Indranil Dey Buys 12,500 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) CEO Indranil Dey bought 12,500 shares of the firm’s stock in a transaction that occurred on Saturday, March 14th. The stock was bought at an average price of $2.00 per share, with a total value of $25,000.00. Following the completion of the acquisition, the chief executive officer owned 12,501 shares of the company’s stock, valued at $25,002. This trade represents a 1,250,000.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Bluejay Diagnostics Stock Up 3.0%

NASDAQ BJDX traded up $0.05 during trading hours on Monday, hitting $1.72. 34,940 shares of the company were exchanged, compared to its average volume of 155,600. The company has a 50 day moving average of $1.90 and a two-hundred day moving average of $3.24. Bluejay Diagnostics, Inc. has a 52-week low of $1.63 and a 52-week high of $16.68. The firm has a market cap of $1.77 million, a price-to-earnings ratio of -0.15 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors own 18.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.